Drug Trial Radar · NCT03773393
A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
May 30, 2019
Primary completion
May 25, 2027
Study completion May 30, 2027
Sponsor
- Lead sponsor
- Cellenkos, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 12, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical research study is to determine whether it is safe and practical to give CK0801 (a Cord blood-derived T-regulatory cell product) to patients with bone marrow failure syndrome. Researchers want to determine the highest possible dose that is safe to be given. Researchers also want to learn if CK0801 may improve the symptoms of bone marrow failure syndrome. Patients enrolled in this study will all have been diagnosed with treatment refractory bone marrow failure syndrome (which includes aplastic anemia, myelodysplastic syndrome, or myelofibrosis). Participants eligible to participate in this study are unable or unwilling to be treated with standard therapy or have failed standard therapy.
Conditions
- Bone Marrow Disease
Interventions
CK0801Biological
CK0801 (a Cord blood-derived T-regulatory cell product)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Severe Infusion Toxicity as Assessed by CTCAE v4.0Time frame: 24 hours post-intervention
- Number of Participants with Regimen Related DeathTime frame: 30 days post-intervention
- Number of Participants with Severe Cytokine Release Syndrome (CRS)Time frame: 30 days post-intervention
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sarcoma Oncology Research Center, Cancer Center of Southern California
Santa Monica, California
The University of Texas MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.